1,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase inhibitors
Graphical abstract
Section snippets
Acknowledgments
We are grateful to NoAb BioDiscoveries Inc. (Mississauga, ON, Canada) and Asinex Ltd (Moscow, Russia) for performing the human NOS inhibition assays.
References and notes (27)
- et al.
Annu. Rep. Med. Chem.
(2009) - et al.
Bioorg. Med. Chem. Lett.
(2007) - et al.
Brain Res.
(2000) - et al.
Bioorg. Med. Chem. Lett.
(2003) - et al.
Bioorg. Med. Chem. Lett.
(1999) - et al.
Tetrahedron Lett.
(1996) - et al.
Proc. Natl. Acad. Sci. U.S.A.
(1987) - et al.
Nat. Rev. Drug Disc.
(2002) - et al.
Arterioscler. Thromb.
(1994)
J. Med. Chem.
Curr. Top. Med. Chem.
Acc. Chem. Res.
Cited by (21)
Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone
2019, European Journal of Medicinal ChemistryCitation Excerpt :Therefore, inhibition of NO represents an effective and attractive therapeutic strategy for the treatment of neurodegenerative diseases. Several classes of Nitic Oxide Synthase (NOS) inhibitors have been reported in the literature [15–23]. Effective NOS inhibitors have been evaluated in animals, but very few clinical trials have been performed in humans [24,25].
TLQP Peptides in Amyotrophic Lateral Sclerosis: Possible Blood Biomarkers with a Neuroprotective Role
2018, NeuroscienceCitation Excerpt :In patients, ALS-related mutations were studied as follows: exon 6 of the TARDBP gene, and all five coding exons of the SOD1 gene were screened by polymerase chain reaction and sequenced using the Big-Dye Terminator v3.1 kit (Applied Biosystems Inc) and an ABI Prism 3130 Genetic Analyzer. A repeat-primed polymerase chain reaction assay was used to screen for the GGGGCC hexanucleotide expansion in the first intron of C9ORF72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011). ALS patients studied showed either: TARDBP-A382T mutation (n = 16), SOD1-G93A mutation (n = 3); expansion in the C9ORF72 gene (n = 5), or no identifiable ALS-related mutation (n = 20).
Dual-Acting Compounds Acting as Receptor Ligands and Enzyme Inhibitors
2017, Design of Hybrid Molecules for Drug DevelopmentDiscovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5- yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine
2012, European Journal of Medicinal ChemistryCitation Excerpt :From these studies, 43 was identified as a potent and selective nNOS inhibitor with exceptional oral bioavailability (91%) without any cardiovascular liabilities (hERG K+ channel inhibition, IC50 >100 μM). As part of our ongoing efforts to find small molecule selective nNOS inhibitors [18–23], herein we report the extended SAR studies on indoline-based thiophene amidine compounds [19] that led to the identification of 43 as a pre-clinical development candidate for the treatment of migraine. The syntheses of all target compounds were carried out according to the procedures described in Schemes 1–4.
Novel, druglike 1,7-disubstituted 2,3,4,5-tetrahydro-1H-benzo[b]azepine- based selective inhibitors of human neuronal nitric oxide synthase (nNOS)
2012, Bioorganic and Medicinal Chemistry Letters